The U.S. Federal Trade Commission (FTC) has released a comprehensive report revealing that major pharmacy benefit managers (PBMs) have inflated drug prices, leading to an estimated $7.3 billion profit at the expense of consumers and the healthcare system. The report highlights disturbing price hikes on specialty drugs, with some increases exceeding 1,000%. Major companies such as CVS, Cigna, and UnitedHealth are accused of abusing their middleman roles and inflating prices on essential medications, including cancer and HIV treatments. Lawmakers are urging for reforms in response to these findings and to address the negative impact of PBM practices on healthcare costs.